首页> 外国专利> Cyclic peptides that inhibit the interaction of vascular cell adhesion molecule 1 (VCAM-1) and fibronectin with integrin very late antigen 4 (VLA-4)

Cyclic peptides that inhibit the interaction of vascular cell adhesion molecule 1 (VCAM-1) and fibronectin with integrin very late antigen 4 (VLA-4)

机译:抑制血管细胞粘附分子1(VCAM-1)和纤连蛋白与整联蛋白极晚期抗原4(VLA-4)相互作用的环肽

摘要

Cyclic peptides of herein described formula wherein: AA1 is an L or D amino acid selected form Ile, Leu, Pro, Tic, Val, tert-Leu, tert-butyl-Ala, Phe, Nle, Met and Ala; AA2 is an L amino acid selected from Leu, Ile, Phe, Val, tert-Leu, Nle, Cha and tert-butyl-Ala; AA3 is an L amino acid selected from Asp or Glu; AA4 is an L amino acid selected from Val Leu, Ile, Phe, Cha, Nle, Nva; and each amino acid is optionally independently alkylated with C1-4 alkyl group; LINKER represents a linking moiety for linking N terminus of AA1 to C terminus of AA4 to form a cyclic peptide containing a heterocyclic ring having 17 to 30 members. The cyclic peptides inhibit the interaction of vascular cell adhesion molecule-1 and fibronectin with integrin very late antigen (VLA) 4 and have therapeutic applications such as in rheumatoid arthritis or multiple sclerosis.
机译:本文所述式的环肽,其中:AA1是选自Ile,Leu,Pro,Tic,Val,叔-Leu,叔丁基-Ala,Phe,Nle,Met和Ala的L或D氨基酸; AA2是选自Leu,Ile,Phe,Val,叔Leu,Nle,Cha和叔丁基-Ala的L氨基酸; AA3是选自Asp或Glu的L氨基酸; AA4是选自Val Leu,Ile,Phe,Cha,Nle,Nva的L氨基酸;每个氨基酸任选地独立地被C 1-4烷基烷基化; LINKER表示用于将AA1的N末端与AA4的C末端连接以形成包含具有17至30个成员的杂环的环肽的连接部分。环状肽抑制血管细胞粘附分子1和纤连蛋白与整联蛋白极晚抗原(VLA)4的相互作用,并具有治疗用途,例如在类风湿性关节炎或多发性硬化症中。

著录项

  • 公开/公告号NZ297530A

    专利类型

  • 公开/公告日2000-02-28

    原文格式PDF

  • 申请/专利权人 ZENECA LIMITED;

    申请/专利号NZ19950297530

  • 发明设计人 DUTTA ANAND SWAROOP;

    申请日1995-12-21

  • 分类号A61K38/39;A61K38/12;C07K14/78;A61K38/08;C07K7/50;

  • 国家 NZ

  • 入库时间 2022-08-22 01:55:30

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号